The Relation Between Macrophage Migration Inhibitory Factor (MIF) and 25(OH) Vitamin D3 Serum Levels in Rheumatoid Arthritis
NCT ID: NCT04315818
Last Updated: 2021-01-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
70 participants
OBSERVATIONAL
2021-03-31
2023-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Some Risk Factors for Developing RA
NCT03624179
Vitamin D as a Key Player in Rheumatoid Arthritis
NCT04344405
The Effect of an Anti-inflammatory Diet in Patients With Rheumatoid Arthritis
NCT05336513
Neutrophil Lymphocyte Ratio and Platelet Lymphocyte Ratio in Rheumatoid Arthritis
NCT03617250
Atherosclerosis in Rheumatoid Arthritis
NCT00990730
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Macrophage Migration Inhibitory Factor is a multipotent cytokine involved in a broad range of functions including induction of proinflammatory mediators as well as demonstrated roles in both innate and adaptive immunity. It was originally identified in the culture medium of activated T lymphocytes as a soluble factor that inhibit random migration of macrophages .
Macrophage Migration Inhibitory Factor induces synoviocytes expression of key proinflammatory genes including TNF, IL-1, IL-6, IL-8. Moreover, it also regulates the function of endothelial cells and B cells and is implicated in the control of synoviocytes proliferation and apoptosis via direct effects on the expression of the tumor suppressor protein P53. In Rheumatoid Arthritis, increased Macrophage Migration Inhibitory Factor levels have been demonstrated in serum, synovial fluid and tissue correlating with disease activity.
Hydroxyapatite 25 vitamin D3 is a hormone primarily synthesized in human skin under the stimulation of ultraviolet radiation. Beyond its endocrine role in bone metabolism, Vitamin D3 is endowed with remarkable immunomodulatory properties. The effects of Vitamin D3 on the immune system include the enhancement of microbicidal ability of monocytes macrophages and the down-modulation of inflammatory cytokines produced by T lymphocytes.
Some epidemiological studies have reported an inverse association between serum 25(OH)vitamin D3 concentrations and Rheumatoid Arthritis disease activity and severity. In addition, some studies have reported inverse correlations between serum 25(OH)vitamin D3 and circulating inflammatory markers and cytokines.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
study group
expermintal
No interventions assigned to this group
control group
placebo
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* satisfying 2010 ACR/ EULAR Rheumatoid Arthritis classification criteria will be included .
Exclusion Criteria
* Individuals with other autoimmune diseases
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assiut University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Marwa Maher Abdelaziz
principal investegator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Doaa Kamal, Doctor
Role: STUDY_CHAIR
Assiut University
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
References
Explore related publications, articles, or registry entries linked to this study.
Santos LL, Morand EF. The role of macrophage migration inhibitory factor in the inflammatory immune response and rheumatoid arthritis. Wien Med Wochenschr. 2006 Jan;156(1-2):11-8. doi: 10.1007/s10354-005-0243-8.
Kim KW, Kim HR. Macrophage migration inhibitory factor: a potential therapeutic target for rheumatoid arthritis. Korean J Intern Med. 2016 Jul;31(4):634-42. doi: 10.3904/kjim.2016.098. Epub 2016 May 12.
Llamas-Covarrubias MA, Valle Y, Navarro-Hernandez RE, Guzman-Guzman IP, Ramirez-Duenas MG, Rangel-Villalobos H, Estrada-Chavez C, Munoz-Valle JF. Serum levels of macrophage migration inhibitory factor are associated with rheumatoid arthritis course. Rheumatol Int. 2012 Aug;32(8):2307-11. doi: 10.1007/s00296-011-1951-6. Epub 2011 May 24.
Ishikawa LLW, Colavite PM, Fraga-Silva TFC, Mimura LAN, Franca TGD, Zorzella-Pezavento SFG, Chiuso-Minicucci F, Marcolino LD, Penitenti M, Ikoma MRV, Sartori A. Vitamin D Deficiency and Rheumatoid Arthritis. Clin Rev Allergy Immunol. 2017 Jun;52(3):373-388. doi: 10.1007/s12016-016-8577-0.
Bilsborrow JB, Doherty E, Tilstam PV, Bucala R. Macrophage migration inhibitory factor (MIF) as a therapeutic target for rheumatoid arthritis and systemic lupus erythematosus. Expert Opin Ther Targets. 2019 Sep;23(9):733-744. doi: 10.1080/14728222.2019.1656718. Epub 2019 Aug 20.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MIF
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.